83 related articles for article (PubMed ID: 12218913)
1. [Prophylactic antiretroviral therapy after sexual exposure to HIV: 93 cases].
Timsit FJ; Maillard A; Spindler E; Taquin Y; Deniaud F; Ferchal F; Morel P; Janier M
Ann Dermatol Venereol; 2002; 129(6-7):866-9. PubMed ID: 12218913
[TBL] [Abstract][Full Text] [Related]
2. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients.
Quirino T; Niero F; Ricci E; Pusterla L; Carradori S; Gabbuti A; Iemoli E; Landonio S; Faggion I; Bonfanti P;
Antivir Ther; 2000 Sep; 5(3):195-7. PubMed ID: 11075939
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
Kahn JO; Martin JN; Roland ME; Bamberger JD; Chesney M; Chambers D; Franses K; Coates TJ; Katz MH
J Infect Dis; 2001 Mar; 183(5):707-14. PubMed ID: 11181146
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV.
Pinkerton SD; Holtgrave DR; Bloom FR
AIDS; 1998 Jun; 12(9):1067-78. PubMed ID: 9662204
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
[TBL] [Abstract][Full Text] [Related]
6. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
[TBL] [Abstract][Full Text] [Related]
7. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Winston A; McAllister J; Amin J; Cooper DA; Carr A
HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
[TBL] [Abstract][Full Text] [Related]
8. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
Eiros Bouza JM; Ortega Lafont M; Ortiz de Lejarazu R; Bachiller Luque P; de Luis Román DA
An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297
[TBL] [Abstract][Full Text] [Related]
9. Cost of preventing HIV infection after sexual exposure.
Lindbloom EJ; Stevermer JJ
J Fam Pract; 1998 Oct; 47(4):251-2. PubMed ID: 9789505
[No Abstract] [Full Text] [Related]
10. [Early treatment of sexual exposure to human immunodeficiency virus].
Derancourt C; Drobacheff C; Verraes S; Beguinot I; Bernard P
Ann Dermatol Venereol; 2000 Jan; 127(1):122-4. PubMed ID: 10717578
[No Abstract] [Full Text] [Related]
11. AIDS in the Third World: how to stop the HIV infection?
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
[TBL] [Abstract][Full Text] [Related]
12. New recommendations on health care worker exposure to HIV.
Woodward J
STEP Perspect; 1996; 8(3):8-10. PubMed ID: 11364268
[TBL] [Abstract][Full Text] [Related]
13. HIV/AIDS following sexual assault in Jamaican children and adolescents: a case for HIV post-exposure prophylaxis.
Steel-Duncan JC; Pierre R; Evans-Gilbert T; Rodriquez B; Christie CD
West Indian Med J; 2004 Oct; 53(5):352-5. PubMed ID: 15675503
[TBL] [Abstract][Full Text] [Related]
14. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
15. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
16. Chemoprophylaxis after occupational exposure to human immunodeficiency virus in forensic autopsy.
Kibayashi K; NG'walali PM; Tsunenari S
Nihon Hoigaku Zasshi; 1998 Apr; 52(2):163-4. PubMed ID: 9711070
[No Abstract] [Full Text] [Related]
17. CDC considers 'morning after' therapy for sexual exposure. Centers for Disease Control and Prevention.
AIDS Policy Law; 1997 Jun; 12(12):4. PubMed ID: 11364408
[TBL] [Abstract][Full Text] [Related]
18. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
[TBL] [Abstract][Full Text] [Related]
19. [Post-exposure HIV prevention: eligibility of patients recently infected by sexual exposure].
Sudre P; San Millán Ruiz D; Fagard C; Perrin L; Hirschel BJ
Schweiz Med Wochenschr; 1999 Feb; 129(8):314-8. PubMed ID: 10189668
[TBL] [Abstract][Full Text] [Related]
20. Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir.
Bourry O; Brochard P; Souquiere S; Makuwa M; Calvo J; Dereudre-Bosquet N; Martinon F; Benech H; Kazanji M; Le Grand R
AIDS; 2009 Feb; 23(4):447-54. PubMed ID: 19240457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
